Baseline characteristics of the COVID-19 cases
| Total (N=113) | |
| Male, n (%) | 70 (61.9) |
| Age at symptoms (years) | |
| Median (IQR) | 58 (53–63) |
| Age class at symptoms (years), n(%) | |
| ≤50 | 23 (20.4) |
| 50–60 | 43 (38.1) |
| >60 | 47 (41.6) |
| Location of patient at occurrence of symptoms, n(%) | |
| Home | 75 (67) |
| Hospital | 35 (31.3) |
| On arrival for LT | 2 (1.8) |
| Missing | 1 |
| Indication for LT, n (%) | |
| Decompensated cirrhosis with or without HCC* | 77 (68.1) |
| HCC | 20 (17.7) |
| Other† | 16 (14.2) |
| Aetiology, n (%) | |
| Alcohol | 30 (26.5) |
| Alcohol+NASH | 8 (7.1) |
| Alcohol+HCV active or inactive | 5 (4.4) |
| AIH+PBC+PSC | 17 (15) |
| HBV | 12 (10.6) |
| HCV active or inactive | 9 (8) |
| NASH | 8 (7.1) |
| Other | 24 (21.2) |
| Comorbidities,N(%) | |
| No | 29 (25.7) |
| Diabetes mellitus | 45 (39.8) |
| Arterial hypertension | 26 (23) |
| BMI>30 kg/m2 | 23 (20.4) |
| Current or former tobacco smoker | 18 (15.9) |
| Kidney function impairment‡ | 12 (10.6) |
| Chronic obstructive lung disease | 5 (4.4) |
| Coronary artery disease | 4 (3.5) |
| Other | 6 (5.3) |
| Number of comorbidities class, n (%) | |
| 0 | 29 (25.7) |
| 1 | 46 (40.7) |
| 2 | 24 (21.2) |
| ≥3 | 14 (12.4) |
| Drugs, n (%) | |
| No | 63 (55.8) |
| Beta blockers | 37 (32.7) |
| ACE inhibitors or angiotensin II receptor antagonists | 7 (6.2) |
| Beta blockers+ACE inhibitors | 6 (5.3) |
| MELD score pre-COVID-19, n (%) | |
| Median (IQR) | 16 (11–21) |
| <15 | 42 (37.2) |
| 15–19 | 34 (30.1) |
| ≥20 | 37 (32.7) |
| Child-Pugh score pre-COVID-19,§ n (%) | |
| Median (IQR) | 8 (7–10) |
| 5–6 | 25 (23.6) |
| 7–9 | 42 (39.6) |
| ≥10 | 39 (36.8) |
| Missing | 1 |
| International Norm INR pre-COVID-19 | |
| Median (IQR) | 1.4 (1.2–1.8) |
| Bilirubin (mg/dL) pre-COVID-19 | |
| Median (IQR) | 2.7 (1–8) |
| Creatinine (mg/dL) pre-COVID-19 | |
| Median (IQR) | 0.9 (0.8–1.3) |
| Ascites pre-COVID-19,§ n (%) | |
| 0=no | 34 (32.7) |
| 1=only at ultrasound | 17 (16.3) |
| 2=moderate | 32 (30.8) |
| 3=severe or tense ascites | 6 (5.8) |
| 4=refractory | 15 (14.4) |
| Missing | 3 |
| Hepatic encephalopathy pre-COVID-19,§ n (%) | |
| 1=absent | 81 (77.9) |
| 2=grades 1–2 | 21 (20.2) |
| 3=grades 3–4 | 2 (1.9) |
| Missing | 3 |
Pre-COVID-19 denotes most recent value before symptoms.
*72 of 77 patients without HCC and 5 of 77 with HCC.
†Re-LT for chronic rejection or hepatic artery thrombosis; autosomal dominant polycystic liver disease; neuroendocrine tumour; primary sclerosing cholangitis; surgical biliary complication.
‡P-creatinine >2 mg/dL
§6 patients without cirrhosis were excluded.
AIH, autoimmune hepatitis; BMI, Body Mass Index; HCC, hepatocellular carcinoma; INR, international normalised ratio; LT, liver transplant; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.